Spectral Medical Revenue
Biotechnology Research • 
Toronto, Ontario, Canada • 21-50 Employees
Spectral Medical revenue & valuation
| Annual revenue | $1,495,359 |
| Revenue per employee | $44,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,800,000 |
| Total funding | $21,299,999 |
Key Contacts at Spectral Medical
Chris Seto
Chief Executive Officer
Edward Mccormack
Director
Company overview
| Headquarters | 135 The West Mall, Unit 2, Toronto, ON M9C 1C2, CA |
| Phone number | +12024022313744665 |
| Website | |
| NAICS | 541714 |
| SIC | 384 |
| Founded | 1991 |
| Employees | 21-50 |
| Socials |
Spectral Medical Email Formats
Spectral Medical uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@spectraldx.com), used 48.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@spectraldx.com | 48.3% |
{first name}{last name} | johndoe@spectraldx.com | 41.4% |
{last name}{last name} | doedoe@spectraldx.com | 6.9% |
{first name} | john@spectraldx.com | 3.4% |
About Spectral Medical
Spectral Medical is a Phase 3 company advancing the fight against endotoxic septic shock through an innovative theranostic approach. This unique strategy combines the EAA™ Endotoxin Activity Assay, the only FDA-cleared diagnostic for the risk of developing sepsis, with targeted rapid therapy using Toraymyxin™ (PMX). PMX is a Polymyxin B extracorporeal direct hemoadsorption column which is highly effective in removing endotoxin in the bloodstream. Already approved in Japan and Europe (1994 and 2002 respectively), PMX has been safely used on over 340,000 patients. Spectral holds exclusive U.S. development and commercialization rights for PMX since 2009, with a distribution agreement for Canada since 2010. In July 2022, the FDA granted Breakthrough Device Designation to PMX for treating endotoxic septic shock, a condition that affects around 330,000 people in North America annually. Spectral is currently conducting the Tigris Trial, a confirmatory study evaluating PMX combined with standard care vs. standard care alone in a 2:1 randomized trial of 150 patients, utilizing Bayesian statistics to assess its effectiveness. The trial methods are detailed in the Critical Care publication “Bayesian methods: a potential path forward for sepsis trials." https://doi.org/10.1186/s13054-023-04717-x
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Spectral Medical has 24 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Spectral Medical's funding history, including investment rounds, total capital raised, and key backers.
Spectral Medical Tech Stack
Discover the technologies and tools that power Spectral Medical's digital infrastructure, from frameworks to analytics platforms.
Video players
JavaScript libraries
CDN
Web servers
JavaScript libraries
Programming languages
Security
Blogs
Page builders
Analytics
Video players
Saudi Arabia
Switzerland
United States
Portugal
United Kingdom
Poland
Frequently asked questions
4.8
40,000 users
